Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia
Recruitment status was Recruiting
The investigators would like to know the association of gene polymorphisms and metabolic adversities in clozapine-treated patients with schizophrenia in Taiwan.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia|
|Study Start Date:||May 2010|
|Estimated Study Completion Date:||April 2011|
The atypical antipsychotics, such as olanzapine, risperidone, quetiapine, and ziprasidone, are effective in treating both the positive and negative symptoms in schizophrenia (Kelleher et al., 2002). However, atypical antipsychotics have been linked to several forms of morbidity, including obesity, hyperlipidemia, and type 2 diabetes mellitus (DM) (Bergman and Ader, 2005; Jin et al., 2004; Melkersson and Dahl, 2004). Compared with the general population, life expectancy in schizophrenic patients is shorter by as much as 20%, attributable to higher rates of suicide, accidental deaths, and natural causes such as cardiovascular disease and DM (Harris and Barraclough, 1998). Several studies have suggested that these metabolic abnormalities may lead to a greater vulnerability to cardiovascular disease and thus may contribute to the excessive mortality among schizophrenic patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01324167
|Contact: Chun-Hsin Chen, MD||886-2-29307930 ext email@example.com|
|Taipei Medical University-WanFang Hospital||Recruiting|
|Contact: Chun-Hsin Chen, MD 886-2-29307930 ext 53961 firstname.lastname@example.org|
|Principal Investigator:||Chun-Hsin Chen, MD||Taipei Medical University WanFang Hospital|